KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Assets: 2017-2024

Historic Non-Current Assets for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $13.2 million.

  • Aquestive Therapeutics' Non-Current Assets fell 11.22% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 11.22%. This contributed to the annual value of $13.2 million for FY2024, which is 19.74% down from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Non-Current Assets is $13.2 million, which was down 19.74% from $16.5 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Non-Current Assets peaked at $18.3 million during FY2020, and registered a low of $13.2 million during FY2024.
  • Its 3-year average for Non-Current Assets is $15.6 million, with a median of $16.5 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first spiked by 79.63% in 2020, then fell by 19.74% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Non-Current Assets (Yearly) stood at $18.3 million in 2020, then dropped by 19.31% to $14.7 million in 2021, then rose by 16.61% to $17.2 million in 2022, then decreased by 4.25% to $16.5 million in 2023, then decreased by 19.74% to $13.2 million in 2024.